Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy-Reference-Cited by-同舟云学术

Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy

Published:2015-05-20 Issue:1 Volume:15 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Tomioka Atsushi,Tanaka Nobumichi,Yoshikawa Motokiyo,Miyake Makito,Anai Satoshi,Chihara Yoshitomo,Okajima Eijiro,Hirayama Akihide,Hirao Yoshihiko,Fujimoto Kiyohide

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/article/10.1186/s12885-015-1429-0/fulltext.html

Reference32 articles.

1. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972;22(4):232–40.

2. Cooperberg MR, Lubeck DP, Penson DF, Mehta SS, Carroll PR, Kane CJ. Sociodemographic and clinical risk characteristics of patients with prostate cancer within the Veterans Affairs health care system: data from CaPSURE. J Urol. 2003;170(3):905–8.

3. Onozawa M, Hinotsu S, Tsukamoto T, Oya M, Ogawa O, Kitamura T, et al. Recent trends in the initial therapy for newly diagnosed prostate cancer in Japan. Jpn J Clin Oncol. 2014;44(10):969–81.

4. Tanaka N, Fujimoto K, Hirayama A, Yoneda T, Yoshida K, Hirao Y. Trends of the primary therapy for patients with prostate cancer in Nara uro-oncological research group (NUORG): a comparison between the CaPSURE data and the NUORG data. Jpn J Clin Oncol. 2010;40(6):588–92.

5. Tanaka N, Fujimoto K, Hirayama A, Samma S, Momose H, Kaneko Y, et al. The primary therapy chosen for patients with localzed prostate cancer between the university hospital and its affiliated hospital in Nara Uro-Oncological Research Group redistration. BMC Urol. 2011;11:6.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Initial [18F]DCFPyL PET/CT in treatment-naïve prostate cancer: correlation with post-ADT PSA outcomes and recurrence;European Journal of Nuclear Medicine and Molecular Imaging;2024-04-02

2. Graphene quantum dot based ultrasensitive probe for biosensing of prostate cancer biomarkers: current updates and future challenges;Advances in Natural Sciences: Nanoscience and Nanotechnology;2022-03-01

3. Bone-Targeted Calcium Phosphate-Polymer Hybrid Nanoparticle Co-Deliver Zoledronate and Docetaxel to Treat Bone Metastasis of Prostate Cancer;Journal of Pharmaceutical Sciences;2021-02

4. Prognostic Value of Platelet Counts in Patients with Metastatic Prostate Cancer Treated with Endocrine Therapy;UROL J;2020

5. Impact of cancer service centralisation on the radical treatment of men with high‐risk and locally advanced prostate cancer: A national cross‐sectional analysis in England;International Journal of Cancer;2019-01-17